How does ferroptosis induction by ailanthone connect to the HIF-1α/LINC01956 pathway?

OPEN

The abstract states ailanthone decreases GBM growth via ferroptosis induction and also via the HIF-1α/LINC01956 pathway, but doesn't explain if these are independent mechanisms or how they interconnect. Clarifying this relationship is important for understanding the drug's complete mechanism of action. Gap type: unexplained_observation Source paper: Ailanthone disturbs cross-talk between cancer cells and tumor-associated macrophages via HIF1-α/LINC01956/FUS/β-catenin signaling pathway in glioblastoma. (None, None, PMID:39639311)

Priority: 0.71 Domain: neuro-oncology Hypotheses: 0
📊 Landscape Analysis

Landscape Summary: How does ferroptosis induction by ailanthone connect to the HIF-1α/LINC01956 pathway? is a 0.71 priority gap in neuro-oncology. It has 0 linked hypotheses with average composite score 0.000. Status: open.

Key Unanswered Questions

Key Researchers

Colonna, Sevlever, et al. (TREM2 biology)

Clinical Trials

How does ferroptosis induction by ailanthone connect to the HIF-1α/LINC01956 pathway? — INVOKE-2 (completed)

📈 Living Dashboards
0
Hypotheses
0.000
Top Score
0.000
Avg Score
0
Debates
0.00
Avg Quality
0%
Resolution
0
Mechanistic Families
Gap Resolution Progress0%

Hypothesis Score Distribution

🏆 Competing Hypotheses (Ranked by Score)

No hypotheses linked to this gap yet.

🌊 Knowledge Graph Connections

No knowledge graph edges recorded

🕑 Activity Feed
update on knowledge_gap by None 2026-04-12T05:54
update on knowledge_gap by None 2026-04-12T05:54
update on knowledge_gap by None 2026-04-12T05:54
update on knowledge_gap by None 2026-04-12T05:54
update on knowledge_gap by None 2026-04-12T05:54
💬 Discussion

No discussions yet. Be the first to comment.

📋 Investigation Sub-Tasks

Create sub-tasks to investigate specific aspects of this gap:

  • Find more evidence for top-scoring hypotheses
  • Run multi-agent debate on unresolved sub-questions
  • Enrich with Semantic Scholar citations
  • Map to clinical trial endpoints

← Back to All Gaps